Rocket Report: Chinese launch firm raises big money; Falcon 9 back to the Bahamas

NASA’s Space Launch System is conducting a second countdown rehearsal at Kennedy Space Center after a prior hydrogen leak interrupted a practice countdown, with the outcome determining whether Artemis II can launch as planned next month or face delays into April or later. Separately, several US allies — notably Germany, Spain, the United Kingdom, Canada and Australia — are committing government funds to develop domestic commercial launch capabilities, though recent failures such as Orbex’s raise questions about near-term execution and credibility.

Analysis

Market structure: Sovereign funding by Germany, Spain, Canada, Australia and others creates a two-tier market — national-backed small/mid launchers (beneficiaries: domestic startups and Tier-1 subcontractors) versus global heavy-lift incumbents (neutral-to-positive for primes like LMT/RTX/BA that win subcontracts). Expect regional launch capacity to rise materially over 3–5 years (plausible capacity increase 20–50%), compressing small-sat per-kg pricing and accelerating price competition for rideshare slots.

Risk assessment: Immediate tail risk is operational (SLS hydrogen leak and Artemis II delay within 0–60 days) that can dent supplier sentiment and bump short-term equities by 10–30% on re-rating. Medium/long risks (6–36 months+) include export controls, range/insurance bottle‑necks and chronic undercapitalization of startups; a single high-profile failure or bankruptcy could trigger sector-wide repricing and consolidation.

Trade implications: Favor defense primes and established commercial players that have recurring government contracts; tactically overweight RKLB (Rocket Lab) and aerospace ETFs (ITA or XAR) while underweight speculative micro-launchers (e.g., small caps with <$100m cash runway). Use 6–12 month option call spreads on RKLB to capture upside if national programs proceed; add on >15% pullbacks or after successful launch milestones within 30 days.

Contrarian angles: The market underestimates the pace of consolidation and the value of government-backed domestic contractors — Europe/Canada suppliers could re-rate as procurement becomes localized. Conversely, consensus may be overexcited about many greenfield launchers; expect 40–60% of current startups to fail or be acquired over 3 years, creating mispricing opportunities in selected survivors and suppliers.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in RKLB (Rocket Lab) funded from cash; use a 6–12 month horizon and target 30–50% upside if Artemis II/test milestones succeed within 60 days or if sovereign contracts flow in over 6–12 months.
• Increase weight in aerospace & defense ETFs (ITA or XAR) by +2% allocation versus benchmark, favoring primes LMT and RTX; expect stable cashflows and government backlog to outperform small-cap launchers over 12–36 months.
• Short or avoid speculative micro-launchers with <USD100m cash runway (example: small-cap A-tier startups or tickers with similar profiles) and consider a 1–2% short exposure; add size if earnings/burn forecasts miss by >20% or a major launch failure occurs.
• Implement an options trade: buy a 9–12 month RKLB call spread (buy ATM, sell 40–60% OTM) sized for 0.5–1% portfolio risk to hedge event-driven volatility around launch tests; add on any >15% equity pullback within 30 days.
• Monitor three triggers before scaling: (1) Artemis/SLS countdown outcome within 0–60 days, (2) national budget approvals for launcher subsidies within 90–180 days, (3) a startup funding runway <12 months revealed in filings — act (add/trim) when any trigger activates.